Меню
Идёт набор NCT05531474

Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial

Без фазы С лечением Cardiovascular Complication Bariatric Surgery Candidate

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Bariatric Surgery, Medical Weight Management.
Кому может быть актуально
Состояния в реестре: Cardiovascular Complication, Bariatric Surgery Candidate. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Канада
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Обзор

The primary objective of this study is to evaluate if, in patients with severe obesity (body mass index (BMI) ≥30 kg/m2) and high-risk cardiovascular disease (CVD), bariatric surgery compared to medical weight management (MWM) safely reduces the risk of major cardiovascular events. The cost-effectiveness of bariatric surgery will also be examined. Separate sub-studies will be performed to examine the relationship between bariatric surgery and mental health and cognition (BRAVE-Mind), cardiac structure and function, genomics, proteomics and metabolomics.

Вмешательства

  • Процедура Bariatric Surgery
    Bariatric surgery involves either gastric bypass, sleeve gastrectomy, or duodenal switch, performed at the discretion of the surgeon and according to local practice standards.
  • Поведенческое Medical Weight Management
    The current standard medical practice for weight loss that is available at the local participating centre, reflecting the local standard of care

Первичные конечные точки

  • Cardiovascular Outcomes [Срок оценки: Through study completion, expected average of 6 years]
  • BRAVE-Mind Sub-study Measures [Срок оценки: 3 years]
Вторичные конечные точки (8)
  • All-cause mortality [Срок оценки: Through study completion, expected average of 6 years]
  • Cardiovascular mortality [Срок оценки: Through study completion, expected average of 6 years]
  • Myocardial infarction [Срок оценки: Through study completion, expected average of 6 years]
  • Stroke [Срок оценки: Through study completion, expected average of 6 years]
  • Hospitalization for heart failure [Срок оценки: Through study completion, expected average of 6 years]
  • New onset or remission of type 2 diabetes as per Diabetes Canada / American Diabetes Association Guidelines [Срок оценки: Through study completion, expected average of 6 years]
  • New onset atrial fibrillation as assessed by ECG or heart rhythm monitoring [Срок оценки: Through study completion, expected average of 6 years]
  • Cost effectiveness analysis, measured in quality adjusted life years [Срок оценки: Through study completion, expected average of 6 years]

Критерии участия

Критерии включения

  • Body mass index ≥30 kg/m2; OR BMI ≥30 kg/m2 to 34.9 kg/m2 and have type 2 diabetes or are \>55 years of age
  • Age ≥18 years
  • High-risk CVD, defined as the presence of any one of the following:
  • High-risk coronary artery disease (CAD) (i.e., history of MI, percutaneous coronary intervention, coronary artery bypass grafting, or stenoses ≥ 50% in 2 or more major coronary arteries)
  • Left ventricular ejection fraction (LVEF) \< 40%
  • Heart failure with preserved ejection fraction (LVEF \> 40%) and either HF hospitalization in the last 2-years or N-terminal pro b-type natriuretic peptide (NT-proBNP) \> 300 pg/ml or BNP \> 100 pg/ml in the past 12 months
  • Documented atrial fibrillation (AF) with CHA2DS2-VASc ≥2 stroke risk score
  • History of any stroke
  • Documented peripheral arterial disease (PAD) (i.e., peripheral revascularization of the iliac, infra-inguinal or carotid arteries; limb or foot amputation for arterial vascular disease; or ≥50% carotid or peripheral artery stenosis)

Критерии исключения

  • Hospital admission for HF, myocardial infarction, stroke or coronary revascularization within 30 days of randomization
  • Percutaneous coronary intervention with a drug eluting stent within 90 days of randomization.
  • Pregnancy
  • Contraindication to bariatric surgery
  • Prior bariatric surgery, other than gastric banding
  • Life expectancy \<2 years from non-cardiovascular causes
  • Inability to provide informed consent

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

Канада · 1 центр
  • Hamilton Health Sciences — Hamilton

Идентификаторы

NCT: NCT05531474 · BRAVE-Full Trial

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗